Microbix to JV with Hunan Biopharma on $200 Million Flu Facility
publication date: Nov 2, 2009
Microbix has signed a joint venture agreement with the Hunan Biopharmaceutical Co. Ltd., a state-owned enterprise, to construct a very large, $200 million facility dedicated to influenza vaccine production. The facility will be Asia's largest flu plant and the third largest vaccine facility in the world. Microbix and Hunan Biopharma will each own 50% of the JV. Microbix originally announced plans for the JV well over a year ago. More details...
Stock Symbol: (TSX: MBX)
Sorry... this feature or article is only available to subscribers.